GlassScriptPhysician profile
Jared Michael Roberts
NPI 1164659389
$2,555.20
in general payments reported to CMS, 2019-2025
33 companies · $403 in 2025
The $403 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $284 · 2021: $497 · 2022: $352 · 2023: $376 · 2024: $347 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,125.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $411.16 | 2019-2025 | Lo Loestrin Fe, Orilissa, Ubrelvy |
| Astellas Pharma US INC | $267.69 | 2019-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $236.08 | 2024-2025 | Gemtesa, Myfembree |
| Amgen INC. | $213.36 | 2019-2023 | Evenity, Prolia |
| Coopersurgical, INC. | $177.39 | 2019-2022 | |
| Hologic Sales and Service, LLC | $141.02 | 2020-2025 | Aptima, Novasure, Myosure Tissue Removal Device |
| Mayne Pharma Commercial LLC | $117.90 | 2022-2025 | |
| Exeltis, USA INC. | $95.51 | 2022-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $92.78 | 2019-2023 | |
| Aspira Women'S Health INC | $92.07 | 2021 | |
| Baxter Healthcare | $86.00 | 2024 | Perclot |
| Organon LLC | $74.78 | 2022-2025 | Nexplanon |
| Mylan Pharmaceuticals INC. | $70.38 | 2021-2022 | |
| Pfizer INC. | $68.78 | 2021-2024 | |
| Shield Therapeutics INC | $48.03 | 2024-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $32.44 | 2021-2022 | |
| Agile Therapeutics, INC. | $30.94 | 2021-2022 | |
| Boston Scientific Corporation | $28.74 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $28.65 | 2019-2020 | |
| Tempus Ai, INC | $26.36 | 2024 | |
| Duchesnay USA Incorporated | $23.91 | 2019 | |
| Novo Nordisk INC | $22.31 | 2019 | |
| Roche Diagnostics Corporation | $20.95 | 2021 | |
| Alexion Pharmaceuticals, INC. | $19.08 | 2022 | |
| Lupin INC. | $16.86 | 2021 | |
| Minerva Surgical, INC | $16.19 | 2025 | |
| Millicent US INC | $15.86 | 2023 | Intrarosa |
| Sage Therapeutics, LLC | $15.50 | 2025 | Zurzuvae |
| Ethicon US, LLC | $14.48 | 2025 | Enseal, Harmonic |
| Dusa Pharmaceuticals, INC. | $13.40 | 2019 | |
| Becton, Dickinson and Company | $12.72 | 2023 | Bd Onclarity |
| Amag Pharmaceuticals, INC. | $12.29 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.